Fluoxymesterone
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict SKIP-PERMANENT HIGH
Hepatotoxicity is among the worst of any oral AAS, the aggression-promoting profile actively conflicts with brain priorities, and zero brain or longevity upside justifies the liver/CV/neurobehavioral risk — no plausible bloodwork or genetic finding flips this verdict.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype) | SKIP-PERMANENT | Aggression promotion, sleep disruption, hepatotoxicity, HPG suppression, and CV strain all conflict with brain-as-#1. Zero cognitive upside. |
30-50, executive maintenance | SKIP-PERMANENT | Same logic, plus rising baseline CV risk. |
50+, mild cognitive decline | SKIP-PERMANENT | CV/hepatic risk grossly outweighs any plausible benefit. |
Anxiety-prone | SKIP-PERMANENT | aggression/irritability profile can destabilize. |
High athletic load, tested status | SKIP-PERMANENT | WADA S1 banned, detectable for weeks-months. |
Sleep-disordered | SKIP-PERMANENT | directly worsens sleep. |
Recovery-focused (post-injury, post-illness) | SKIP | better non-hepatotoxic alternatives (oxandrolone, nandrolone, testosterone TRT) for tissue recovery. |
Strength/anabolic-focused (untested, accepting AAS risk) | SKIP | better strength tools exist (test base + non-17α stacks). Halo's only differentiator is the aggression effect, which is a liability in most contexts. |
Combat-sport pre-fight, accepting all risk, single-event use | E | here, the historical use-case has largely been replaced by safer aggression strategies (cortisol/adrenaline timing, stimulant titration, psychological prep). One-time exposure has lower hepatotoxicity than a cycle but still nonzero risk and detectability if tested. Not endorsed. |
- Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)SKIP-PERMANENT
Aggression promotion, sleep disruption, hepatotoxicity, HPG suppression, and CV strain all conflict with brain-as-#1. Zero cognitive upside.
- 30-50, executive maintenanceSKIP-PERMANENT
Same logic, plus rising baseline CV risk.
- 50+, mild cognitive declineSKIP-PERMANENT
CV/hepatic risk grossly outweighs any plausible benefit.
- Anxiety-proneSKIP-PERMANENT
aggression/irritability profile can destabilize.
- High athletic load, tested statusSKIP-PERMANENT
WADA S1 banned, detectable for weeks-months.
- Sleep-disorderedSKIP-PERMANENT
directly worsens sleep.
- Recovery-focused (post-injury, post-illness)SKIP
better non-hepatotoxic alternatives (oxandrolone, nandrolone, testosterone TRT) for tissue recovery.
- Strength/anabolic-focused (untested, accepting AAS risk)SKIP
better strength tools exist (test base + non-17α stacks). Halo's only differentiator is the aggression effect, which is a liability in most contexts.
- Combat-sport pre-fight, accepting all risk, single-event useE
here, the historical use-case has largely been replaced by safer aggression strategies (cortisol/adrenaline timing, stimulant titration, psychological prep). One-time exposure has lower hepatotoxicity than a cycle but still nonzero risk and detectability if tested. Not endorsed.
▸ Subjective experience (deep)
Reported effects (per anecdote — Dylan should not infer this is a recommendation):
- Onset: ~1-2 hr oral
- Peak effects: 2-4 hr (halflife ~9.5 hr)
- Characteristic effects: sharp surge in aggression, confidence, "willingness to engage," strength feels disproportionate to mass gained, mental tunnel-vision, often insomnia and short fuse with non-training stressors. Many users describe a "mean" or "edge" quality distinct from testosterone or trenbolone aggression.
- Crash / taper: lipid panel and liver enzymes deteriorate fast; mood often dips on cessation due to HPG suppression; strength gains drop quickly (large water/glycogen component).
This profile is exactly the wrong fit for someone whose stated #1 priority is brain — sustained AR-mediated aggression, sleep disruption, and HPG suppression are all neurobehavioral net-negatives.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Anabolic effects plateau quickly (3-4 weeks); hepatotoxicity does not plateau and accumulates linearly with exposure.
- Recommended cycle: None recommended for Dylan. Historical lore caps total exposure at 2-4 weeks max with full bloodwork pre/mid/post.
- Reset protocol: Post-cycle therapy (PCT) historically with HCG → SERM (clomiphene/tamoxifen). Liver recovery requires complete cessation — there's no "reset" while on.
▸ Stacking deep dive
Synergistic with
None recommended. Historical bodybuilding stacks paired halo with non-17α injectables (testosterone enanthate, trenbolone, masteron) to limit oral hepatotoxicity to halo alone — but all combinations compound CV and neurobehavioral risk.
Avoid stacking with
- Other 17α-alkylated orals (methyltestosterone, oxandrolone, stanozolol, methandrostenolone): hepatotoxicity additive, often catastrophic.
- Alcohol: hepatic stress additive — but Dylan is zero-alcohol so n/a.
- NSAIDs (chronic): hepatic + renal stress additive.
- Other CNS stimulants at high dose (modafinil, amphetamines): insomnia + aggression amplified.
Neutral / safe co-administration
N/a — not recommending co-administration.
▸ Drug interactions deep dive
- CYP3A4 substrate (minor) — interactions less prominent than with E2-active AAS.
- Warfarin / anticoagulants: AAS broadly potentiate warfarin → bleeding risk.
- Insulin / oral hypoglycemics: AAS can lower insulin requirements (relevant for diabetics, not Dylan).
- Corticosteroids: additive hepatic and CV strain.
▸ Pharmacogenomics
- SLCO1B1 polymorphisms affect hepatic uptake of 17α-AAS — variants associated with elevated hepatotoxicity risk. Worth checking from 23andMe raw data once results land (~June 2026).
- CYP3A5 expressers may metabolize slightly faster but clinical relevance modest given hepatic burden is structural (17α-methyl), not enzymatic.
- AR CAG repeat length modulates androgenic sensitivity — short repeats correlate with stronger androgenic response (acne, alopecia, aggression, prostate effects); long repeats with blunted response. Not a safety lever for halo specifically.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gray-market UGL (underground lab) | Various | $50-120 / 50× 10 mg tabs | Low — heavy counterfeit/dosing-inaccuracy in the AAS UGL space | Halo is among the most counterfeited AAS due to high price-per-mg vs cheaper-to-produce alternatives (often actually methyltest or dianabol) |
| Research-chem ("for laboratory use") | Various | $80-150 / 50× 10 mg | Low | Same counterfeit risk |
| US Rx | None practical | n/a | n/a | Halotestin pulled from US market — no legitimate Rx pathway |
▸ Biomarkers to track (deep)
Not relevant — verdict is SKIP-PERMANENT. If the verdict were ever revisited, baseline + biweekly liver panel (ALT/AST/GGT/bilirubin/ALP), full lipid panel, CBC (hematocrit), blood pressure, total/free T, LH/FSH, SHBG, E2 (sensitive), PSA, creatinine.
▸ Controversies / open debates Live debate
- Aggression effect — pharmacological vs psychological: some researchers argue the "halo aggression" reputation is partly placebo + selection effect (users seeking aggression find it). Others point to mechanistic plausibility (high AR affinity + no E2 buffering). Likely both — but the practical net effect on user behavior is consistently reported.
- Hepatotoxicity dose-threshold: older clinical lit suggests low doses (5 mg/day) have near-zero serious hepatic events. Modern bodybuilding doses (20-40 mg/day) have substantially higher risk. The dose-response is real but the no-effect threshold is not well established and 17α-alkylation creates structural hepatic stress at any dose.
- Comparison to trenbolone for aggression: tren is sometimes cited as the more aggression-promoting compound; halo is sometimes cited as more "mean" / "edge" specifically. Both are bad fits for Dylan's brain-priority profile.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-PERMANENT HIGH. Hepatotoxicity is class-leading-bad among 17α-AAS, aggression-promoting profile actively conflicts with brain-priority and quality-of-life goals at 20yo, and there is no plausible context where halo beats safer alternatives (oxandrolone for cutting, testosterone TRT for baseline, modafinil/bromantane/caffeine for cognitive edge, sport-psychology and arousal-titration for pre-fight aggression). Bloodwork and 23andMe results would not flip this — the structural hepatotoxicity and behavioral profile are not personalizable away.
▸ Open questions / gaps Open
- None research-relevant for Dylan. Halo is a thoroughly characterized, mostly historical compound — modern AAS literature treats it as a known-bad option retained mostly for sport-history interest.
- If the question were "single-dose pre-competition exposure for an actual sanctioned-but-untested fight" the calculus shifts marginally (single 10-20 mg dose has lower hepatic risk than a cycle), but the aggression effect is unreliable as a competitive-edge tool and detectability if random-tested is high. Still SKIP.
▸ Sources (full, with our context)
- Kicman AT. "Pharmacology of anabolic steroids." Br J Pharmacol. 2008. — class-level pharmacology including 17α-AAS hepatotoxicity mechanism.
- Llewellyn W. Anabolics (11th ed.) — comprehensive AAS reference incl. fluoxymesterone profile, dosing history, anecdotal aggression reports.
- Niedfeldt MW. "Anabolic Steroid Effect on the Liver." Curr Sports Med Rep. 2018. — review of 17α-AAS hepatotoxicity (peliosis, adenoma, HCC).
- Pope HG, Kanayama G, Hudson JI. "Risk factors for illicit anabolic-androgenic steroid use in male weightlifters." Drug Alcohol Depend. 2012. — psychiatric/behavioral effects.
- Historical Upjohn/Pharmacia Halotestin product monograph — clinical dosing, indications, withdrawn safety profile.
- Combat-sport / bodybuilding anecdote literature (forums, trainer interviews) — pre-fight aggression dose lore. Treat as anecdotal-tier evidence.